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Abstract
Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate
whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV
infected individuals having $300 CD4+ cells/mm3 compared to untreated controls. When the results of two large clinical
trials, ESPRIT and SILCAAT, showed no clinical benefit from IL-2 therapy, IL-2 administration was halted in STALWART.
Because IL-2 recipients in STALWART experienced a greater number of opportunistic disease (OD) or death and adverse
events (AEs), participants were asked to consent to an extended follow-up phase in order to assess persistence of IL-2
effects.
Methodology: Participants in this study were followed for clinical events and AEs every 4 months for 24 months.
Unadjusted Cox proportional hazards models were used to summarize death, death or first OD event, and first grade 3 or 4
AE.
Principal Findings: A total of 267 persons were enrolled in STALWART (176 randomized to the IL-2 arms and 91 to the no
therapy arm); 142 individuals in the IL-2 group and 80 controls agreed to enter the extended follow-up study. Initiation of
continuous ART was delayed in the IL-2 groups, but once started, resulted in similar CD4+ cell and viral load responses
compared to controls. The hazard ratios (95% CI) for IL-2 versus control during the extension phase for death or OD, grade 3
or 4 AE, and grade 4 AE were 1.45 (0.38, 5.45), 0.43 (0.24, 1.63) and 0.20 (0.04, 1.03), respectively. The hazard ratios for the AE
outcomes were significantly lower during the extension than during the main study.
Conclusions: Adverse events associated with IL-2 cycling did not persist upon discontinuation of IL-2. The use of IL-2 did not
impact the subsequent response to initiation of cART.
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Introduction
STALWART [1] was designed to evaluate the safety, immu-
nologic, and virologic effects of intermittent interleukin 2 (IL-2) in
asymptomatic HIV-infected persons not receiving antiretroviral
therapy (ART) and having a CD4+ cell count $300 cells/mm3.
The study tested the hypothesis that IL-2 with or without peri-
cycle ART would maintain or increase CD4+ cell counts
compared to controls receiving neither IL-2 nor ART. The
maintenance of higher CD4+ values with IL-2 was hypothesized to
permit the safe deferral of continuous ART (cART) for a longer
period of time compared to controls. Overall, 267 individuals were
randomized: 89 to receive IL-2, alone; 87 to receive IL-2 and peri-
cycle ART; and 91 untreated controls. Most (78.7%) were ART
naı¨ve; the remainder, according to protocol, had not taken any
ART within the preceding year. When the results of ESPRIT and
SILCAAT showed that IL-2 combined with continuous ART
conferred excess toxicity without clinical benefit [2] further IL-2
administration was halted in STALWART, and safety and efficacy
data were reported [1]. Although IL-2 recipients in STALWART
experienced a significant increase in CD4+ cell count (the change
from baseline to week 32 was approximately 130 cells/mm3
higher in IL-2 recipients compared to controls), grade 3 or 4
adverse events were also significantly more common among those
given IL-2. Moreover, a trend was observed for an increased risk
of opportunistic diseases or death among IL-2 recipients compared
to untreated controls. Thus, the IL-2 induced CD4+ cell count
elevation did not appear to accurately represent an improvement
in immune function.
Compared to controls, cART was less likely to have been started
among IL-2 recipients during the study period. This was likely
attributable to the higher CD4+ counts observed among those
receiving IL-2, which, when taken at face value, would have less
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frequently led to the initiation of ART. This ‘‘delay’’ in the
initiation of antiretrovirals may have accounted, at least in part,
for the increased opportunistic events observed among those who
received IL-2; notably, no STALWART participant who experi-
enced an opportunistic disease was on continuous ART when the
event occurred. At the time of STALWART closure, the hazard
ratios (IL-2 groups combined versus controls) for opportunistic
disease (OD) or death and for moderate or severe adverse events
(AEs) were 5.8 (0.76–45.1, p = 0.09) and 2.9 (1.4–6.0, p = 0.004).
Because the persistence of the IL-2 induced CD4+ cell quantitative
versus qualitative discordance was unknown as well as the long-
term toxicity, participants were asked to consent to an additional
two years of unblinded clinical observation in an extended follow-
up phase of STALWART.
Methods
Ethics
The STALWART study was approved by the institutional
review board (IRB) or institutional ethics committee (IEC) of each
clinical site and of the University of Minnesota, and informed
consent was obtained from all participants. A letter of amendment
to the protocol was issued in April 2009 continuing unblinded
safety assessments for an additional two years beyond the planned
follow-up. Re-consent was obtained from patients if required by
that individual IRB/IEC.
Design
The design, methods, and results of the STALWART trial have
been previously published [1]. During the extended follow-up
phase, patients were seen at four-month intervals for study visits
where information on CD4+ cell count and HIV-RNA was
collected. The following clinical events were reported as they
occurred: deaths, opportunistic disease (OD) events (AIDS-
defining events, bacterial pneumonia, and salmonella) and adverse
events of grade 3 or 4 severity, as assessed by site investigators
using a standard National Institute of Allergy and Infectious
Diseases (NIAID) Division of AIDS toxicity table.
Statistical Methods
Because the primary focus of the extended follow-up was on
adverse consequences of IL-2 administration, and because the
original study showed no difference in the rates of AEs and ODs
between the two IL-2 groups, key events are summarized for both
IL-2 groups combined versus control. Significance testing for
differences between treatment groups is performed using chi
square and Kruskal-Wallis tests. Kaplan-Meier survival curves are
used to summarize time to initiation of continuous ART from
randomization to the end of the extended follow-up phase. This
analysis is based on all patients randomized, and follow-up is
censored at the end of the main study for those patients who did
not participate in the extended follow-up. Cox proportional
hazards models, stratified by geographic region (7 strata total), are
used to summarize all-cause death, the combined endpoint of
death or first OD event, and first grade 4 or grade 3/4 AE. These
events are summarized for two follow-up periods: from random-
ization through 28 February 2009, the originally planned end of
study; and from 1 March 2009 to 28 February 2011, the extended
follow-up phase. An expanded model with an interaction term
between treatment indicator and time period was used to assess
whether the hazard ratios (HR) differed between the two time
periods. Rates are shown per 100-person months follow-up.
Other analyses, shown for the 3 treatment groups, are restricted
to the patients who participated in the extended follow-up. During
this phase, follow-up visits continued every four months according
to a visit schedule that was generated at the time of randomization.
Therefore, for analyses of the extended follow-up phase, visit
windows were re-defined at four-month intervals (62 months)
following February 28, 2009, and visit-specific measurements were
imputed from data available within that visit window and closest to
the anniversary date.
Analyses of CD4+ cell count following initiation of cART were
performed using a mixed longitudinal regression model with
random patient effects and unstructured covariance matrix. These
models were adjusted for age, gender, baseline CD4+ cell count
and HIV-RNA, and last measured CD4+ cell count and HIV-
RNA prior to ART initiation. For this analysis, CD4+ cell counts
after ART initiation are ascribed to follow-up visits in a method
similar to that described in the previous paragraph.
Results
Study Population
The extended follow-up phase of STALWART began on 1
March 2009 and continued to a common closing date of 28
February 2011. Among the 267 persons who entered STAL-
WART, 222 (83.1%) entered the extended follow-up study
(Figure 1): 69/89 recipients of IL-2; 73/87 recipients of IL-2+
peri-cycle ART (IL2+ART); and 80/91 controls. Overall, 80.7%
of the patients assigned IL-2 compared to 87.9% of the control
group participated in extended follow-up (p = 0.14). Across
treatment groups, based on the last available measurement prior
to beginning the extension phase, individuals who participated in
extended follow-up were more likely to have undetectable HIV-
RNA levels (26.6% versus 11.6%, p= 0.04). No other character-
istics examined were determinates of participation in the extension
phase.
The baseline (as randomized into STALWART) characteristics
were similar across treatment groups for patients participating in
extended follow-up (Table 1). At the time the extension phase
began, 24.6% of IL-2 recipients (30.4% of those randomized to IL-
2 alone and 19.2% of those randomized to IL-2+ART) had
already started cART, compared to 43.8% of controls (p = 0.003).
As a likely consequence of these differences, the median HIV-
RNA was higher (13,895 copies/ml versus 3,045, p = 0.001) and
percent with HIV-RNA #400 copies/ml was lower (21.1 versus
36.3, p = 0.01) for IL-2 recipients. The median CD4+ cell counts
were 474 cells/mm3 among IL-2 recipients and 412 cells/mm3
among controls (p = 0.06). There were no differences in HIV-RNA
or CD4 across treatment groups after stratification by whether
patients had started cART (data not shown).
Extended Follow-Up
Initiation of continuous ART. Upon being informed of
results of the ESPRIT and SILCCAT trials, the STALWART
protocol team, in recognition that the CD4+ cell counts might not
reliably represent immune function, had recommended the
initiation of cART for all IL-2 recipients. However, the decision
to initiate ART was made by investigators and study participants
on an individual basis. As seen in Figure 2, patients in the IL-2
groups initiated cART significantly later following initial random-
ization than those in the control group (p = 0.03). The CD4+ cell
count at which ART was started was similar for both IL-2
recipients and controls: the median (IQR) CD4+ cell count
proximal to the initiation of ART for the IL-2 group was 300 (230,
381) cells/mm3 versus 303 (232, 353) cells/mm3 for untreated
controls. By the end of extended follow-up, 71.8% of the IL-2
group vs 78.8% of the control group had started cART.
IL-2: Persistence of Effects after Discontinuation
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e47506
CD4+ cells. At month 24 of extended follow-up, a month 24
CD4+ count was available for 48 recipients of IL-2 alone, 47
recipients of IL-2+ART, and 56 controls. For those given IL-2
alone and IL-2+ART, respectively, the mean (mean change from
baseline) CD4+ cell counts were 496 cells/mm3 (+69.6 cells/
mm3) and 512 cells/mm3 (+42.6 cells/mm3), while the mean
Figure 1. Study design and CONSORT flow diagram.
doi:10.1371/journal.pone.0047506.g001
Table 1. Characteristics of STALWART participants at study entry and at the beginning of the extension phase.
Study Entry Beginning of Extension Phase
IL-2 (n=176) Control (n= 91) IL-2 (n=142) Control (n = 80)
Age at baseline, median years 35 36 36 36
Gender, % female 17.0 17.6 17.6 17.5
Race, %
Asian 25.6 24.2 26.1 26.3
Black 4.5 8.8 2.8 8.8
White/other 69.9 67.0 71.1 65.0
Likely mode of HIV infection (%)*
Sexual, same sex 58.5 61.5 60.6 63.8
Sexual, opposite sex 39.8 37.4 39.4 35.0
Injection drug use 3.4 0.0 2.8 0.0
Other or unknown 3.4 2.2 2.1 2.5
Taking ART (%) 0.0 0.0 24.6 43.8
CD4+ cell count (median) 407 432 474 412
HIV-RNA (median copies/ml) 22,360 24,328 13,895 3,045
HIV-RNA #400 copies/ml (%) 3.4 4.4 21.1 36.3
*more than one may apply.
doi:10.1371/journal.pone.0047506.t001
IL-2: Persistence of Effects after Discontinuation
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CD4+ cell count (mean change from baseline) among controls was
559 cells/mm3 (+106.6 cells/mm3). Because of the delay in
starting cART in the IL-2 groups, CD4+ cell counts were also
analyzed from the time of initiation of cART. The adjusted CD4+
cell count response to cART was similar across all groups
(Figure 3). Once started, the CD4+ cell response to cART
appeared to have been unaffected by prior IL-2 or peri-cycle ART
when compared to controls.
HIV RNA. At the end of the extended follow-up, 49 IL-2
recipients, 48 IL-2+ART recipients, 57 controls had an available
month 24 viral load. Between 69% and 74% of all treatment
groups had HIV RNA levels #400 copies/ml. When treatment
groups were compared following the initiation of cART, 90.7% of
IL-2 recipients and 89.7% of those given IL-2+ ART had a viral
load of #400 copies by month 4 after initiation of cART,
compared to 95.7% in the control group (p = 0.55). Compared to
controls, neither IL-2 nor peri-cycle ART appeared to impact the
subsequent viral load response to cART (Figure 4).
Adverse events. The numbers of patients experiencing grade
3 and 4 adverse events are shown in Table 2 for the two study
periods. While IL-2 recipients were at higher risk of experiencing a
grade 3 or 4 event during the main study, the hazard ratio
appeared to favor the IL-2 groups during the extension
(HR=0.63, 95% CI=0.24–1.63, p= 0.34). The p-value for
treatment group by time period interaction (a comparison of the
HRs from the two time periods) was 0.01, indicating that the HR
significantly declined from the first period to the second. Findings
are similar when the analysis is restricted to grade 4 AEs
(HR=0.20, 95% CI= 0.04, 1.03, p = 0.05; interaction p-val-
ue = 0.04).
Opportunistic disease and death. Of the 222 individuals
who entered the extended follow-up phase of STALWART, 212
(95.5%) were known to be alive at the end of the study. Results for
death and the combination endpoint of death or first OD event are
displayed for the two phases of the trial in Table 2. Four persons (3
IL-2 recipients and 1 control) died during the extension
(HR=1.63, 95% CI= 0.17–15.71, p = 0.67). Eleven patients (8
versus 3) died or experienced an opportunistic event; the hazard
ratio for this outcome was 1.45 (95% CI= .38–5.45, p = 0.59),
compared to 2.94 during the main study (p = 0.31 for difference
between study periods).
Discussion
The follow-up phase of STALWART was designed to assess the
outcome of patients who received IL-2 alone or IL-2+ peri-cycle
ART. Because there was a trend towards an excess of clinical
events among IL-2 recipients and because these events occurred at
relatively elevated CD4+ cell counts, it was important to
determine if this trend (which did not attain statistical significance)
persisted after the discontinuation of IL-2. The elevated risk of
adverse events associated with IL-2 administration did not persist
during the extended follow-up phase. While a trend toward more
opportunistic events in the IL-2 groups was observed during the
extension, this may be in part explained by the delay in starting
ART in the treatment groups assigned to IL-2.
Figure 2. Time to initiation of continuous ART.
doi:10.1371/journal.pone.0047506.g002
IL-2: Persistence of Effects after Discontinuation
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Figure 3. CD4+ cell count response after initiating continous ART.
doi:10.1371/journal.pone.0047506.g003
Figure 4. HIV-RNA after initiating continuous ART.
doi:10.1371/journal.pone.0047506.g004
IL-2: Persistence of Effects after Discontinuation
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Despite its ability to increase CD4+ T cells, IL-2 with
continuous ART has been shown to confer no clinical benefit or
protection from opportunistic diseases or death compared to
continuous ART alone, but was associated with an increased risk
of adverse events [2]. STALWART, which was undertaken before
the results of ESPRIT and SILCAAT were known and stopped
once these results became available, likewise showed no clinical
benefit of IL-2 with or without peri-cycle ART when compared to
no treatment among individuals for whom, at the time, treatment
was not clinically indicated [1]. Because of an apparent increase in
the number of opportunistic diseases or death among those who
received any IL-2 in STALWART, as well as their occurrence at
relatively elevated proximal CD4+ cell counts, participants were
asked to participate in a 2 year extended follow-up study. Overall
approximately 83% of participants were followed in the observa-
tion phase, representative of the initial randomized STALWART
population. Over the follow-up period, compared to controls,
persons who received IL-2 at any time did not experience an
increased rate of grade 3/4 clinical events or opportunistic
diseases/death. The subsequent response to continuous ART,
once started, did not appear to have been impacted by prior IL-2
with or without peri-cycle ART. This observation is important
given the concern that peri-cycle ART might lead to drug
resistance and predispose to treatment failure once cART has been
initiated, although in the initial randomized study peri-cycle ART
was not clearly associated with the emergence of drug resistance
based on population sequencing [1].
Although SILCAAT and ESPRIT showed that IL-2 plus cART
did not lead to a reduction in incidence of OD/Death compared
to ART alone, there were significantly more AEs – particularly
thromboembolic events – among IL-2 recipients. The reasons for
the lack of clinical benefit of IL-2, despite its ability to markedly
increase CD4+ cell count, has not been fully elucidated. There
have been no demonstrable long-term increases of plasma HIV
RNA or intracellular HIV DNA [1,3–8]. However, it is likely that
the polyclonal CD4+ increases with prolonged survival of central
memory and naı¨ve T-lymphocytes [9–13] observed do not result
in immunologically relevant protection. Various hypotheses have
been proposed for this observation, including functional impair-
ment of the IL-2-induced CD4+ cells, negative modulatory effects
from other CD4+ subsets such as CD4+CD45RO-CD25+ foxP3
expressing cells, or lack of impact on the GALT [14–16]. Although
immune activation measured by T-cell turnover is reduced among
IL-2 recipients [10,11,17], IL-2 has been shown to acutely increase
inflammatory markers, including D-dimer [18–20], which may
contribute to hypercoagulability and to the increased death rate
among ESPRIT participants having the greatest IL-2-induced
CD4+ cell expansions [21].
Although the findings in ANRS 119, which like STALWART
included IL-2 only versus untreated control arms, suggested that
IL-2 usage might safely allow deferral of ART, its sample size was
smaller and it was not powered to detect differences in clinical
events [22]. The STALWART study suggests that this deferral
may come at a price. However, it is possible that other
immunomodulatory agents, such as IL-7 may have a future role
[23,24].
In conclusion, STALWART demonstrated that IL-2 conferred
no clinical benefit among asymptomatic HIV-infected persons not
receiving antiretroviral therapy. While its administration led to a
delay in the initiation of ART, this delay was associated with a
trend towards a greater incidence of OD/Death and a statistically
significant increase in AEs. Over the extended follow up, event
rates in the IL-2 groups remained higher than controls, but
differences were not statistically significant. Although the time
from discontinuation of IL-2 to the reversal of its effects could not
be measured in this extension study, the effects of IL-2, with or
without peri-cycle ART, were not persistent and not associated
with any lingering impact on the response to subsequent ART.
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